Post-earnings recap
Reported
Wed, Nov 6, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
ADMA Biologics reported a loss per share of $0.19, but did not disclose revenue figures. The stock fell by 3.11% following the report, likely due to the lack of guidance and clarity on financial performance. Investors may be concerned about the company's future prospects without specific targets or revenue updates.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.19 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach regarding future performance. They emphasized the importance of operational efficiency.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company is focusing on operational improvements and cost management.